Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma
First-line immunotherapy is effective and safe for the treatment of patients with ESCC. Rapid and deep tumor shrinkage may serve as an early predictive biomarker for longer survival.
Authors
- Eiji Shinozaki
- Shota Fukuoka (ORCID: https://orcid.org/0000-0001-9460-4486)
- Akira Ooki (ORCID: https://orcid.org/0000-0001-7618-5775)
- S. Udagawa
- K. Chin
- Kei Yoshino (ORCID: https://orcid.org/0000-0002-8062-4379)
- Keitaro Shimozaki (ORCID: https://orcid.org/0000-0002-4559-5699)
- Hiroki Osumi (ORCID: https://orcid.org/0000-0002-4742-0446)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Mariko Ogura (ORCID: https://orcid.org/0000-0002-1004-8425)
- Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
- Moritake Tamba
Institutions
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100171
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00